Inflammation

, Volume 36, Issue 1, pp 35–41 | Cite as

Is the IL-10 Promoter Polymorphism at Position -592 Associated with Immune System-Related Diseases?

  • Mojgan Noroozi Karimabad
  • Mohammad Kazemi Arababadi
  • Elham Hakimizadeh
  • Hassan Yousefi Daredori
  • Mahmood Nazari
  • Gholamhossein Hassanshahi
  • Derek Kennedy
Article

Abstract

Immune responses are the main causes of immune system-related diseases such as hypersensitivities and autoimmunity. It has also been established that cytokines play key roles in the regulation of immune responses which have been shown to be important in the pathogenesis of the diseases. IL-10, the main anti-inflammatory cytokine, is produced by several immune cells such as T regulatory and Th2 lymphocytes, activated macrophages, B regulatory lymphocytes as well as other cell types. It plays a key role in the regulation of immune responses after microbe elimination (homeostasis) and against self-antigens to prevent hypersensitivity and autoimmune diseases, respectively. Studies showed that a single nucleotide polymorphism (SNP) at the -592 position of IL-10 is associated with its regulation of expression. This review addresses the recent information regarding the association of the polymorphism at position -592 of IL-10 with immune-related diseases including type 2 diabetes with and without nephropathy, multiple sclerosis, and asthma with an emphasize on Iranian patients.

KEY WORDS

IL-10 polymorphism diabetes nephropathy multiple sclerosis asthma 

References

  1. 1.
    Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216–220.PubMedCrossRefGoogle Scholar
  2. 2.
    Arababadi, M.K., B.N. Ahmadabadi, and D. Kennedy. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion. doi:10.1111/j.1537-2995.2012.03575.x.
  3. 3.
    van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897–901.PubMedCrossRefGoogle Scholar
  4. 4.
    Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. The Journal of Allergy and Clinical Immunology 123: 749–755. quiz 756–747.PubMedCrossRefGoogle Scholar
  5. 5.
    Li, Y.P., V. Latger-Canard, L. Marchal, et al. 2006. The regulatory role of dendritic cells in the immune tolerance. Biomedical Materials and Engineering 16: S163–S170.PubMedGoogle Scholar
  6. 6.
    Karjalainen, J., J. Hulkkonen, M.M. Nieminen, et al. 2003. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clinical and Experimental Allergy 33: 78–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Sawcer, S., G. Hellenthal, M. Pirinen, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.PubMedCrossRefGoogle Scholar
  8. 8.
    Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomarkers in Medicine 4: 755–759.PubMedCrossRefGoogle Scholar
  9. 9.
    Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5 ≏ 32 mutation and multiple sclerosis in patients of south-eastern of Iran. Laboratory Medicine 41: 31–33.CrossRefGoogle Scholar
  10. 10.
    Arababadi, M.K., R. Mosavi, H. Teimori, et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Annals of Saudi Medicine 32(2): 127–130.Google Scholar
  11. 11.
    Arababadi, M.K., H. Abousaidi, G. Hassanshahi, et al. 2011. Association of exon 9 but not intron 8 VDR polymorphisms with asthma in south-eastern Iranian patients. Iranian Journal of Basic Medical Science 14: 107–115.Google Scholar
  12. 12.
    Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5–B11.PubMedCrossRefGoogle Scholar
  13. 13.
    Orihara, K., N. Dil, V. Anaparti, et al. 2011. What’s new in asthma pathophysiology and immunopathology? Expert Review of Respiratory Medicine 4: 605–629.CrossRefGoogle Scholar
  14. 14.
    Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: a study on south-eastern Iranian diabetic patients. Biomarkers in Medicine 6(1): 89–95.CrossRefGoogle Scholar
  15. 15.
    Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. Journal of Endocrinological Investigation 31: 694–699.PubMedGoogle Scholar
  16. 16.
    Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iranian Red Crescent Medical Journal 13(10): 752.PubMedGoogle Scholar
  17. 17.
    Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Research and Clinical Practice 87: 33–37.PubMedCrossRefGoogle Scholar
  18. 18.
    Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iranian Journal of Basic Medical Science 12: 100–104.Google Scholar
  19. 19.
    Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Annals of Saudi Medicine 29: 413.PubMedCrossRefGoogle Scholar
  20. 20.
    Groux, H., and F. Cottrez. 2003. The complex role of interleukin-10 in autoimmunity. Journal of Autoimmunity 20: 281–285.PubMedCrossRefGoogle Scholar
  21. 21.
    Howell, W.M., and M.J. Rose-Zerilli. 2006. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Familial Cancer 5: 143–149.PubMedCrossRefGoogle Scholar
  22. 22.
    Sabat, R., G. Grutz, K. Warszawska, et al. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21: 331–344.CrossRefGoogle Scholar
  23. 23.
    Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19: 683–765.PubMedCrossRefGoogle Scholar
  24. 24.
    Booy, R., S. Nadel, M. Hibberd, et al. 1997. Genetic influence on cytokine production in meningococcal disease. Lancet 349: 1176.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang, Y., J. Zhang, C. Tian, et al. 2011. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer’s disease: a meta-analysis. Journal of Neurological Sciences 303: 133–138.CrossRefGoogle Scholar
  26. 26.
    Lopez, P., C. Gutierrez, and A. Suarez. 2010. IL-10 and TNFalpha genotypes in SLE. Journal of Biomedicine and Biotechnology 2010: 838390.PubMedGoogle Scholar
  27. 27.
    Scapini, P., C. Lamagna, Y. Hu, et al. 2011. B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2011: 12.Google Scholar
  28. 28.
    Li, M.O., and R.A. Flavell. 2008. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468–476.PubMedCrossRefGoogle Scholar
  29. 29.
    Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iranian Journal of Kidney Diseases 4: 302–306.Google Scholar
  30. 30.
    Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. International Journal of Immunogenetics 37: 1–5.CrossRefGoogle Scholar
  31. 31.
    Arababadi, M.K., M. Mirzaei, S.M.A. Sajadi, et al. 2011. Interleukin (IL)-10 gene polymorphisms is associated with type 2 diabetes with and without nephropathy: a study of patients from the South-East region of Iran. Inflammation 35(3): 797–802.CrossRefGoogle Scholar
  32. 32.
    Chang, J.H., H.R. Cha, D.S. Lee, et al. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 5: e12925.Google Scholar
  33. 33.
    Mtiraoui, N., I. Ezzidi, M. Kacem, et al. 2009. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes/Metabolism Research and Reviews 25: 57–63.PubMedCrossRefGoogle Scholar
  34. 34.
    Kung, W.J., C.C. Lin, S.H. Liu, et al. 2011. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809–813.CrossRefGoogle Scholar
  35. 35.
    Ezzidi, I., N. Mtiraoui, M. Kacem, et al. 2009. Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clinical Endocrinology 70: 401–407.PubMedCrossRefGoogle Scholar
  36. 36.
    Ishii, M., G. Hasegawa, M. Fukui, et al. 2005. Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/ml) of antibodies to glutamic acid decarboxylase. Immunology Letters 99: 180–185.PubMedCrossRefGoogle Scholar
  37. 37.
    Scarpelli, D., M. Cardellini, F. Andreozzi, et al. 2006. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 55: 1529–1533.PubMedCrossRefGoogle Scholar
  38. 38.
    Ascherio, A., K.L. Munger, K.C. Simon. Vitamin D and multiple sclerosis. Lancet Neurology 9: 599–612.Google Scholar
  39. 39.
    Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine 1: 111–119.PubMedCrossRefGoogle Scholar
  40. 40.
    Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.PubMedCrossRefGoogle Scholar
  41. 41.
    Nosratabadi, R., B.N. Ahmadabadi, M.K. Arababadi, et al. 2011. Association of polymorphism in the -592 region of IL-10 with multiple sclerosis in south-eastern Iranian patients. Iranian Red Crescent Medical Journal 32(2): 127–130.Google Scholar
  42. 42.
    Almeras, L., B. Meresse, J. Seze, et al. 2002. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. European Cytokine Network 13: 200–206.PubMedGoogle Scholar
  43. 43.
    Forte, G.I., P. Ragonese, G. Salemi, et al. 2006. Search for genetic factors associated with susceptibility to multiple sclerosis. Annals of the New York Academy of Sciences 1067: 264–269.PubMedCrossRefGoogle Scholar
  44. 44.
    Luomala, M., T. Lehtimaki, H. Huhtala, et al. 2003. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurologica Scandinavica 108: 396–400.PubMedCrossRefGoogle Scholar
  45. 45.
    Mihailova, S., M. Ivanova, A. Mihaylova, et al. 2005. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. Journal of Neuroimmunology 168: 138–143.PubMedCrossRefGoogle Scholar
  46. 46.
    Wergeland, S., A. Beiske, H. Nyland, et al. 2005. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. European Journal of Neurology 12: 171–175.PubMedCrossRefGoogle Scholar
  47. 47.
    Azarpira, N., A. Borhani Haghighi, M. Pourjafar, et al. 2010. Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurologica Taiwanica 19: 107–111.PubMedGoogle Scholar
  48. 48.
    Pickard, C., C. Mann, P. Sinnott, et al. 1999. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. Journal of Neuroimmunology 101: 207–210.PubMedCrossRefGoogle Scholar
  49. 49.
    Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. The Journal of Allergy and Clinical Immunology 108: 69–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respiratory Medicine 102: 1198–1202.PubMedCrossRefGoogle Scholar
  51. 51.
    Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of asthma: a study on Iranian asthma patients. Southern Medical Journal 104: 422–425.PubMedCrossRefGoogle Scholar
  52. 52.
    Pukelsheim, K., T. Stoeger, D. Kutschke, et al. 2010. Cytokine profiles in asthma families depend on age and phenotype. PLoS One 5: e14299.PubMedCrossRefGoogle Scholar
  53. 53.
    Hakimizadeh, E., M.K. Arababadi, G. Hassanshahi, et al. 2012. Association of -592 region of IL-10 polymorphisms with asthma in south-eastern Iranian patients. Clinical Laboratory 58: 267–271.Google Scholar
  54. 54.
    Zhang, J., H. Chen, L. Hu, et al. 2002. Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression. Zhonghua Yi Xue Za Zhi 82: 114–118.PubMedGoogle Scholar
  55. 55.
    Movahedi, M., S.A. Mahdaviani, N. Rezaei, et al. 2008. IL-10, TGF-beta, IL-2, IL-12, and IFN-gamma cytokine gene polymorphisms in asthma. The Journal of Asthma 45: 790–794.PubMedCrossRefGoogle Scholar
  56. 56.
    Hobbs, K., J. Negri, M. Klinnert, et al. 1998. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. American Journal of Respiratory and Critical Care Medicine 158: 1958–1962.PubMedGoogle Scholar
  57. 57.
    Immervoll, T., S. Loesgen, G. Dutsch, et al. 2001. Fine mapping and single nucleotide polymorphism association results of candidate genes for asthma and related phenotypes. Human Mutation 18: 327–336.PubMedCrossRefGoogle Scholar
  58. 58.
    Kim, S.H., E.M. Yang, H.N. Lee, et al. 2009. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 64: 1221–1225.PubMedCrossRefGoogle Scholar
  59. 59.
    Trajkov, D., J. Mirkovska-Stojkovikj, T. Arsov, et al. 2008. Association of cytokine gene polymorphisms with bronchial asthma in Macedonians. Iranian Journal of Allergy, Asthma, and Immunology 7: 143–156.PubMedGoogle Scholar
  60. 60.
    Zedan, M., A. Settin, M.K. Farag, et al. 2008. Gene polymorphisms of tumor necrosis factor alpha-308 and interleukin-10-1082 among asthmatic Egyptian children. Allergy and Asthma Proceedings 29: 268–273.PubMedCrossRefGoogle Scholar
  61. 61.
    Chatterjee, R., J. Batra, A. Kumar, et al. 2005. Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clinical and Experimental Allergy 35: 914–919.PubMedCrossRefGoogle Scholar
  62. 62.
    Kazemi Arababadi, M., M. Reza Mirzaei, S.M. Ali Sajadi, et al. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran. Inflammation 35: 797–802.Google Scholar
  63. 63.
    Kung, W.J., C.C. Lin, S.H. Liu, et al. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809–813.Google Scholar
  64. 64.
    Hakimizadeh, E., M.K. Arababadi, G. Hassanshahi, et al. Association of -592 region of IL-10 polymorphisms with asthma in south-eastern Iranian patients. Clinical Laboratory 58: 267–271.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Mojgan Noroozi Karimabad
    • 1
  • Mohammad Kazemi Arababadi
    • 2
    • 3
  • Elham Hakimizadeh
    • 4
  • Hassan Yousefi Daredori
    • 5
  • Mahmood Nazari
    • 5
  • Gholamhossein Hassanshahi
    • 1
  • Derek Kennedy
    • 6
  1. 1.Molecular Medicine Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  2. 2.Department of Microbiology, Hematology and Immunology, Faculty of Medicine and Immunology of Infectious Diseases Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  3. 3.Immunology of Infectious Diseases Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  4. 4.Physiology and Pharmacology Research CenterRafsanjan University of Medical SciencesRafsanjanIran
  5. 5.Department of Biochemistry, Faculty of MedicineRafsanjan University of Medical SciencesRafsanjanIran
  6. 6.School of Biomolecular and Physical Science, Eskitis Institute for Cell and Molecular TherapiesGriffith University NathanQueenslandAustralia

Personalised recommendations